Revolutionising Drug Safety
IoT and Blockchain in Pharmacovigilance
Prasanthi Sadhu, Editor, Pharma Focus Asia
The pharmaceutical industry is experiencing a profound transformation, fueled by the integration of advanced technologies and a heightened commitment to patient safety. With the power of digital innovation and AI, pharmacovigilance (PV) is going to play a pivotal role in protecting global health. Traditional PV methods often fall short in keeping up with the complexity and rapid advancements of modern medicine. This is where the integration of the Internet of Things (IoT) and Blockchain technology is turning out to be a game-changing force.
IoT, through its network of interconnected smart devices, facilitates real-time monitoring and data collection on an unparalleled scale. IoT devices - ranging from wearable health trackers to smart pill dispensers - deliver detailed, patient-specific insights that were previously not possible. However, this wealth of data brings challenges in ensuring its integrity, security, and traceability, and this is where Blockchain excels.
Blockchain, with its secure, immutable ledger and decentralised framework, is transforming data management and trust in healthcare. In pharmacovigilance, it ensures that adverse event reports, drug safety data, and supply chain information are transparent, tamperproof, and readily accessible to all stakeholders. IoT and Blockchain forms a powerful, synergistic system that improves the accuracy, efficiency, and reliability of drug safety efforts.
For stakeholders in the healthcare and pharmaceutical sectors, embracing this digital transformation is not just an option—it is essential. The future of pharmacovigilance hinges on collaboration, innovation, and the responsible integration of emerging technologies. By harnessing the power of IoT and Blockchain, we can ensure that drug safety progresses alongside medical advancements, paving way for a healthier, safer world for patients globally.
This issue of Pharma Focus Asia also covers other interesting articles on Revolutionising Drug Safety, Healthcare research with digitalised Clinical Trials and many more. The magazine also covers PHARMA PULSE on Supply with Care: Crafting strategies for clinical trial excellence in the Asia-Pacific – A CDMO Perspective by Kate Park, Head of Business Development APAC, Almac Group; Nicolas Biber, Forecasting and Resupply Operations Lead, 4G Clinical; Rod De Spong, Chief Operating Officer, Douglas CDMO; Karen Montgomery- Douglas and Regional Business Development Manager, Akesa. Please explore the knowledge driven articles and send your valuable suggestions to [email protected].
Author Bio
Prasanthi Sadhu, Editor, Pharma Focus Asia
